This article is more than 5 years old. Information may no longer be current.
VIDEO: Evidence 'reassuring' that biologic therapy safe in IBD patients with cancer history
Click Here to Manage Email Alerts
HONOLULU — Edward V. Loftus Jr., MD, professor of medicine at the Mayo Clinic in Rochester, Minn., discusses his presentation given during a case-based symposium on management of inflammatory bowel disease.
“The case that I presented was … of a young man who had a history of a Hodgkin lymphoma that was thought to be induced by combination therapy with a thiopurine and infliximab,” Loftus said. “The question that I had posed … was, ‘How do we treat this guy going forward?’ He’s now 4 years out from his Hodgkin lymphoma, and yet he’s still having active Crohn’s disease.”
He concluded, “The data that are starting to come out in the last few years are somewhat reassuring that even in patients with a previous history of cancer, it might be reasonable to consider the use of biologic therapy.”
Disclosures: Loftus reports he is an advisory committee/board member for AbbVie, Shire and UCB; a consultant for Celgene, Genentech, Janssen Biotech, MedImmune, Seres Health, Sun Pharmaceuticals, Takeda and Theradiag; and has received grant/research support from AbbVie, Amgen, Bristol-Myers Squibb, Genentech, GlaxoSmithKline, Janssen Biotech, Pfizer, Robarts Clinical Trials, Takeda and UCB.